» Articles » PMID: 26600855

Effects of Rosuvastatin And/or β-carotene on Non-alcoholic Fatty Liver in Rats

Overview
Journal Res Pharm Sci
Specialty Chemistry
Date 2015 Nov 25
PMID 26600855
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of non-alcoholic fatty liver disease (NAFLD) has markedly increased, especially in patients exhibit one or more features of the metabolic syndrome. This study investigates the effect of rosuvastatin (RSV) and/or β-carotene (βC) in NAFLD-induced rats. Rats were classified into nine groups; normal (I), NAFLD-induced with high-fat diet (HFD; II), NAFLD switched to regular diet (RD; III), NAFLD-HFD or NAFLD-RD treated with RSV (IV, V), βC (VI, VII) or both RSV+βC (VIII, IX), respectively. After four weeks, rats were sacrificed to obtain serum samples and liver tissues. Liver histology, lipid profile, liver oxidative stress markers, and adipocytokines were measured. Liver sections of rats with NAFLD-HFD revealed steatosis, lose of hepatic architecture, inflammation and hepatocyte vacuolation with high percentage of cell fibrosis. Serum levels of ALT, AST, ALP, gamma glutamyl transferase (GGT) and lipid profile (triglycerides, cholesterol, LDL and VLDL) were significantly increased (P<0.05) compared with normal. Also, hepatic malondialdehyde level and serum leptin, tumor necrosis factor-alpha (TNF-α) and transforming growth factor-β1 (TGF-β1) were increased. Meanwhile, superoxide dismutase (SOD) activity, GSH content in liver, serum HDL and adiponectin were decreased (P<0.05) vs normal. These changes were observed to a lesser extent in NAFLD-RD group. Administration of RSV or/and βC almost improved all previously mentioned parameters. Moreover, hepatic steatosis was decreased and inflammation was markedly ameliorated with reduction of TNF-α and TGF-β. These results were more pronounced in the groups VIII and IX vs each drug alone. In conclusion RSV and βC could be beneficial for the treatment and prevention of NAFLD. Combined RSV with βC is more effective than RSV alone.

Citing Articles

Bilirubin, once a toxin but now an antioxidant alleviating non-alcoholic fatty liver disease in an autophagy-dependent manner in high-fat diet-induced rats: a molecular and histopathological analysis.

Tavakoli R, Maleki M, Vakili O, Taghizadeh M, Zal F, Shafiee S Res Pharm Sci. 2024; 19(4):475-488.

PMID: 39399727 PMC: 11468170. DOI: 10.4103/RPS.RPS_53_24.


The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review.

Mohammadian K, Fakhar F, Keramat S, Stanek A Antioxidants (Basel). 2024; 13(7).

PMID: 39061866 PMC: 11273623. DOI: 10.3390/antiox13070797.


Concomitant Administration of Rosuvastatin and Lefleunamide in Low doses Synergize Against Complete Freunds Adjuvant (CFA)-Induced Rheumatoid Arthritis in Experimental Model.

Saeed A, El-Shafey M, Helal G, Akool E J Pharm Res Int. 2024; 33(42A):370-382.

PMID: 39055998 PMC: 11271653. DOI: 10.9734/jpri/2021/v33i42a32415.


Tapping into Nature's Arsenal: Harnessing the Potential of Natural Antioxidants for Human Health and Disease Prevention.

Pinilla-Gonzalez V, Rojas-Sole C, Gomez-Hevia F, Gonzalez-Fernandez T, Cereceda-Cornejo A, Chichiarelli S Foods. 2024; 13(13).

PMID: 38998505 PMC: 11241326. DOI: 10.3390/foods13131999.


Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease.

Tyczynska M, Hunek G, Szczasny M, Brachet A, Januszewski J, Forma A Int J Mol Sci. 2024; 25(9).

PMID: 38732128 PMC: 11085010. DOI: 10.3390/ijms25094916.


References
1.
Kameji H, Mochizuki K, Miyoshi N, Goda T . β-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α. Nutrition. 2010; 26(11-12):1151-6. DOI: 10.1016/j.nut.2009.09.006. View

2.
Ohkawa H, Ohishi N, Yagi K . Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2):351-8. DOI: 10.1016/0003-2697(79)90738-3. View

3.
Ansari J, Bhandari U, Pillai K, Haque S . Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats--a preliminary study. Indian J Exp Biol. 2012; 50(3):216-22. View

4.
Kostapanos M, Milionis H, Filippatos T, Nakou E, Bairaktari E, Tselepis A . A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007; 29(7):1403-14. DOI: 10.1016/j.clinthera.2007.07.019. View

5.
Canas J, Damaso L, Altomare A, Killen K, Hossain J, Balagopal P . Insulin resistance and adiposity in relation to serum β-carotene levels. J Pediatr. 2012; 161(1):58-64.e1-2. DOI: 10.1016/j.jpeds.2012.01.030. View